Checkmate 141 and Keynote-040 studies demonstrated a significant OS benefit with the second line of the immune checkpoint inhibitor PD-1 over standard therapy in recurrent or metastatic HNSCC (14, 15). This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.